Accufix Surgical®

Anatomically restoring joint function to patients with arthritic conditions

Accufix Surgical® Inc. is a specialty orthopedic device developer and distributor of The Accu-Joint® Hemi implant system — a revolutionary, FDA-approved treatment for MTP joint disorders that is designed to restore natural motion and preserve your active lifestyle.


Mission Statement
To be an industry leader in developing products intended to improve quality of life for patients, through joint preservation as opposed to joint fusion. We seek to anatomically restore joint function to patients with arthritic conditions.

Leadership

Robert Torney

VP, Sales

David L. Rechberger

Supply Chain
Managing Director, Disruptive MedTech

Jennifer Petersen

Finance
Director, Disruptive MedTech

Stephen Arndt, M.D.

Medical Director

Aaron Shemenski, DPM, FACFAS

VP, Clinical Services

Glenn C. Vitale, DPM, FACFAS

Chief Medical Officer

Jamie Lineberger

Co-chair, Board of Directors

Andy Brown

Co-chair, Board of Directors

Michael Parisi

Board of Directors

Keith Hamilton

Business Advisory Committee

Bonnie Post

Business Advisory Committee

Randy Allard, BSME, MSBME, PE

Engineering, Allard Biomedical Consulting

Active Patents

The Accu-Joint® Implant has been engineered to withstand levels of stress from normal everyday activity as achieved by the fatigue testing requirements associated with FDA approval.

  • 10,765,522: Accu-Joint® system
  • 10,959,851:Hemi implants with Reamer features
  • 11,039,928: Hemi phalangeal implant
  • 11,051,946: Hemi metatarsal implant
  • 11,890,022: 2-Stage MTP Joint Reamer
  • Other patents pending

FDA Approval

On December 8, 2020 Accufix Surgical® received premarket notification of intent to market the Accu-Joint® Hemi Implant from the FDA based on a determination that the device is substantially equivalent to legally marketed predicate devices.

Indication for Use

The Accu-Joint® Hemi Implant, a hemiarthroplasty metatarsal head or phalangeal base implant for the metatarsophalangeal (MTP) joint, is indicated for use in the treatment of patients with degenerative and post-traumatic arthritis in the MTP joint in the presence of good bone stock, along with the following clinical conditions: Hallux Limitus, Hallux Valgus, Hallux Rigidus, and an unstable or painful MTP joint. The Accu-Joint® Hemi Implant is intended to be used with bone cement. The metatarsal head and phalangeal base may not be used together at the same joint.

Strategic Partnerships

Disruptive MedTech strives to be the world’s first and strongest Group Manufacturing Organization and provides turn-key manufacturing and testing of custom, innovative, private branded medical devices.

Academy Medical is a team of veterans, industry experts, and thought leaders that are helping to ensure that the federal procurement community is able to operate in a way that is fast and effective.

Stay up to date on Accufix Surgical®

Join our mailing list and get updates sent directly to your inbox.